$MRNA News
Last published 17h ago
- 17h agoMRNAModerna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and OlderACCESS NewswireModerna, Inc. (NASDAQ:MRNA) today announced the publication of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE® (COVID-19 Vaccine, mRNA) and Comirnaty® (COVID-19 Vaccine, mRNA) among U.S. Veterans aged 65 years and older during the 2025-2026 respiratory virus season. The analysis, published in JAMA Network Open, included 294,499 matched participants in t ...
- 1d agoMRNAModerna to Present at Upcoming Conference in November 2026ACCESS NewswireModerna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Jefferies Global Health Care Conference, on Wednesday, November 18th 11:00am GMT A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be arc ...
- 5d agoMRNAModerna Third Quarter 2026 Conference Call - MODERNA INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to Moderna's third quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answ
- 5d agoMRNAModerna Third Quarter 2026 Conference Call - MODERNA INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to Moderna's third quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answ
- 5d agoMRNAMRKModerna raises 2026 outlook as CEO says newer vaccines are gaining tractionCNBCThe biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
- 5d agoMRNAModerna, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 5d agoMRNAModerna Reports Third Quarter 2026 Financial Results and Provides Business UpdatesACCESS NewswireReports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10%
- 6d agoMRNAHealth Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 VaccinesACCESS NewswireCanada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU® CAMBRIDGE, MA / ACCESS Newswire / November 5,
- 1w agoMRNAModerna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 StudyACCESS NewswireWHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc.
- 1w agoMRNAModerna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual MeetingACCESS NewswireInitial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma CAMBRIDGE, MA / ACCESS Newswire / November 4, 2026 / Moderna, Inc.
- 2w agoGTBPMRNAIOVAGMAB+1Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment MarketGlobeNewswireNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
- 2w agoHYFTMRNAMRKBNTXA Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better TargetsGlobeNewswireAUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
- 2w agoMRNAMRKDoctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fallCNBCSix melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma treatment.
- 2w agoMRNAModerna Named a Top Employer by Science for Twelfth Consecutive YearACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top
- 2w agoMRKMRNAMerck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential SymposiumBusiness WireIntismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV
- 2w agoMRNAMRKModerna shares plunge after leak of partial cancer vaccine dataCNBCModerna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release.
- 3w agoMRNANVOOpenAI acquires startup Orchestra Bio to beef up its biotech businessTechCrunch
- 4w agoMRKMRNAMerck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to makeCNBCHis comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.
- 4w agoHYFTGENBMRNAABSI+1AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestGlobeNewswireNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
- 4w agoMRNAModerna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026ACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. , today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to report its third
- 1mo agoNTHIMRNAMRKJNJ2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New HopeGlobeNewswireDENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of
- 1mo agoMRNAModerna Adds Chief Operating Officer Role as Company Expands into OncologyACCESS NewswireJuan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / Moderna, Inc.
- 1mo agoMRNABernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum - MODERNA INCEarnings Call TranscriptsHi, everyone. Thank you so much for being with us here today. My name is Courtney Breen. I am the farmer analyst here at Bernstein. And I have the privilege of sharing this stage today with Stefan Bansal, CEO of Moderna,
- 1mo agoMRNAModerna Announces Late-Breaking Data to be Presented at ESMO Congress 2026ACCESS NewswirePhase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event via webcast on
- 1mo agoNNVCGILDMRNAPFE+1A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can
- 2mo agoMRNAModerna to Present at Upcoming Conferences in September 2026ACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. , today announced its participation in the following upcoming investor conferences:Morgan Stanley 24th Annual Global Healthcare
- 2mo ago.SPXAEMWBDBTC.CM+12August was the month of the comeback kids. Cramer reviews what drove the biggest winnersCNBCCNBC's Jim Cramer said August was a comeback month for stocks that had been battered by bearish narratives.
- 2mo agoMRNAModerna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior NotesACCESS NewswireProceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debtModerna has also purchased a hedge overlay intended to
- 2mo agoMRNAModerna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 VaccinesACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Applications for
- 2mo agoMRNAModerna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior NotesACCESS NewswireProceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debtModerna will also purchase a hedge overlay intended to
- 2mo agoSBFMBNTXAZNMRNA+1A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityGlobeNewswireNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is
- 2mo agoUS30Y.SPXNVDAWMT+3The Treasury's debt buyback, Walmart earnings, Boise's AI boom and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 2mo agoMRNAMRKUS30Y.SPX+6Target earnings, Canada tariffs, American Airlines' seatback screens and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 2mo agoMRKMRNAPersonalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trialCNBCThe combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
- 2mo agoMRKMRNAMerck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaBusiness WireFirst and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The
- 3mo agoMRNAModerna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVAACCESS NewswiremFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5,
- 3mo agoMRNAModerna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo EbolavirusACCESS NewswirePhase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicatedPhase 1 trial is being conducted in Canada as part of our expanded collaboration with the
- 3mo agoMRNAModerna Second Quarter 2026 Conference Call - MODERNA INCEarnings Call TranscriptsThank you for standing by. Welcome to the Moderna second quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session
- 3mo agoMRNAModerna Second Quarter 2026 Conference Call - MODERNA INCEarnings Call TranscriptsThis video tutorial shows how to install Kali Linux 2017.1 LXDE on VMware Workstation or VMware Workspace. Kali LXD is a very simple and easy-to-use software that can be installed on your computer. To install it, click o
- 3mo agoMRNAModerna Reports Second Quarter 2026 Financial Results and Provides Business UpdatesACCESS NewswireReports second quarter revenue of $0.1 billion, GAAP net loss of $ billion and GAAP EPS of $Reiterates plan to deliver up to 10% revenue growth in 2026Improves 2026 GAAP operating expense outlook by
- 3mo agoMRNAGOOGLWhen will fusion power startup Commonwealth Fusion Systems go public?TechCrunch
- 3mo agoMRNAModerna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid TumorsACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy
- 4mo agoMRNAModerna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026ACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. , today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter
- 4mo agoMRNAModerna Appoints Michael McDonnell to Board of DirectorsACCESS NewswireFormer Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. today announced the
- 4mo agoMRNAJim Cramer says this former Covid market darling is finally investable againCNBCCNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis.
- 4mo agoAMGNMRNATMONVOAnthropic’s Claude Science bets on workflow, not a new model, to win over scientistsTechCrunch
- 4mo agoMRNAModerna Science Day Highlights Expanding Potential of mRNA PlatformACCESS NewswireProvides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting
- 4mo agoMRNAModerna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza VaccineACCESS NewswireFDA Prescription Drug User Fee Act goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. today announced that the U.S. Food and Drug Administration's
- 4mo agoMRNAModerna to Host Investor Event - Science DayACCESS NewswireCAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. today announced that it will host its Investor Event - Science Day at 9:00am ET on Thursday, June 25, 2026.The event will feature an overview
- 4mo agoMRNAModerna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028ACCESS NewswireDr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease FranchisesEster Banque to Join Moderna as Chief Commercial